ISSN: 2517-7370
Cancer is generally referred to as a disease that involves abnormal growth of cells that have the potential to spread in different parts of the body. The disease may be curable if detected in early stages. It is most prevalent disease ...
Explore the journal aims, scope and subject coverage before submission.
View editorial leadership and board information for this journal.
Browse current research articles and article updates from this journal.
Open Access publishing information is available for authors and readers.
He completed his degree in Medicine and Surgery at the University of Turin.His Current Profession is Assistant Professor, at the University of Turin, Oncology Department. He has many publications in national and international journals. His Research achievements are coordinated a multicenter randomized Phase II clinical trial (Vecti-BIL study) to evaluate the effectiveness of Panitumumab (P) in combination with chemotherapy in patients with advanced BTC selected for the absence of KRAS mutations on exon In preclinical experience, he explored alternative molecules such as ET-743 and the Src inhibitor Saracatinib. He has memberships in American Association of Medical Oncology (ASCO), European Society for Medical Oncology (ESMO), Italian Association of Medical Oncology (AIOM). His previous experience is the coordinator of the activities of the multidisciplinary team for the treatment of digestive cancers at the IRCC Candiolo. Biliary tract cancer (BTC) is a rare and lethal disease with very few therapeutic options. Epithelial Growth Factor Receptor (EGFR) pathway activation could be involved in BTC pathogenesis, envisaging a potential role of anti-EGFR monoclonal antibodies.
Discover peer-reviewed open access journals across diverse disciplines.
